Full Breakdown
Israeli Researchers Discover Cannabis Compounds for Fatty Liver Disease Treatment
3/6/2026, 12:29:40 PM
Groundbreaking Research on Cannabinoids
Israeli researchers have identified two compounds from the cannabis plant, Cannabidiol (CBD) and Cannabigerol (CBG), that may lead to the first effective treatment for metabolic dysfunction-associated steatotic liver disease (MASLD), commonly referred to as fatty liver disease. This condition affects approximately one in three adults globally and currently lacks any approved pharmacological treatment. The study, led by Professor Yossi Tam from the Hebrew University of Jerusalem’s School of Pharmacy, was published in *The British Journal of Pharmacology* and reveals how these compounds can enhance liver health by altering energy management and detoxification processes.
Mechanism of Action
The research indicates that CBD and CBG, both non-psychoactive compounds, can improve liver function through a process termed "metabolic remodeling." This involves increasing levels of phosphocreatine, which serves as an energy reserve for the liver, and restoring the activity of enzymes known as cathepsins that facilitate the removal of harmful fats and waste. The study utilized a model of diet-induced obesity in mice, demonstrating that treatment with CBD and CBG not only reduced fat accumulation but also significantly lowered harmful lipid levels, including triglycerides and ceramides, which are linked to insulin resistance and liver inflammation.
Implications for Public Health
The findings are particularly significant given the rising obesity rates in Israel, where nearly 60% of adults are classified as overweight or obese. The increase in obesity correlates with a higher risk of liver diseases, including MASLD. Dr. Ethan Russo, a cannabis research expert not involved in the study, emphasized the public health implications, noting the potential for these compounds to address a growing health crisis.
Clinical Trials and Future Directions
Professor Tam's laboratory has patented the combination of CBD and CBG for metabolic disorders, paving the way for future clinical trials aimed at human applications. Tam expressed his aspiration to develop a cannabinoid-based drug that could provide a safe and effective treatment option for individuals suffering from fatty liver disease and related metabolic disorders.
Criticism and Opposition
While the study presents promising results, it is essential to note that MASLD can often be managed through lifestyle changes such as diet and exercise, particularly if diagnosed early. Critics may argue that reliance on pharmacological solutions could detract from the importance of these preventive measures.
Verbatim Quotes
- “this disease does not have a current drug available whatsoever,” — Prof. Yossi Tam, Hebrew University of Jerusalem
- “The study elucidates the benefits” of CBD and CBG to counteract MASLD, said Russo.” — Dr. Ethan Russo, CReDO Science
- “My hope is to bring a cannabinoid-based drug to help the human population suffering from fatty liver disease and metabolic disorder,” — Prof. Yossi Tam, Hebrew University of Jerusalem
The research on CBD and CBG represents a significant advancement in the quest for effective treatments for fatty liver disease, with the potential to impact public health positively.
